Dmytro Shymkiv told how Darnitsa can speed up the production of medicines

The pharmaceutical company “Darnitsa” plans to significantly reduce the waiting time for the release of new drugs. This was stated by the chairman of the board of directors of Darnitsa – Dmytro Shymkiv. He explained that the increase in the range of products and production rates has become possible due to the use of modern IT technologies in the development, testing and manufacturing of medicines.

According to information from the management of the Darnitsa Group, by the end of 2021 the plant plans to come out with over 25 pharmaceutical brands. Thus, the total number of commodity items will be more than fifty, and every fourth product from this list will be delivered to pharmacy chains 4 months prior to the schedule. This increase in production turnover was facilitated by the systematic introduction of innovative methods and technologies into the company’s work. Dmytro Shymkiv has repeatedly stated this in his interviews and public speeches.

Timely, regular and substantial investments in the amount of approximately UAH 100 million and the early start of digital transformation of production processes had a positive impact on the speed of registration and changes in the drug dossier. Due to this, it was also possible to minimize the risks provoked by quarantine restrictions. Comprehensive modernization allowed the Darnitsa company during 2020 to register a new product every 2 weeks and to re-register its products on a weekly basis.

Speaking about the importance and necessity of digital transformations, Dmytro Shymkiv said that recently there has been a strong tendency to augment the role of the IT industry in the healthcare system. The symbiosis of high technologies and medicine will continue to deepen and progress in the future. This will allow not only to minimize the timing of development, research and production of pharmaceutical products, but also to significantly increase the level of medicine in all areas from prevention and diagnosis to therapy. For example, the employees of “Darnitsa” are already closely engaged in the study of genetic data. These studies will improve the accuracy of predicting potential diseases. Furthermore, the pharmaceutical concern has completely switched to electronic monitoring of drug use and began using digital master files (eTMF) in the process of clinical trials.